pharma · Activated Phosphoinositide 3-Kinase Delta Syndrome · primary immunodeficiency
Pharming Technologies
Pharming Technologies B.V.
Pharming Technologies clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Leiden, NL
- Employees
- 6
- Programs
- 8
- Drugs
- 11
- Patents
- 0
Pharming Technologies projects
8 ClinicalTrials.gov programs sponsored by Pharming Technologies.
Pharming Technologies has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
LE 3302
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
KL1333 2025-104B
Pharming Technologies B.V.
Adult patients with primary mitochondrial disease
1 trial -
LE 7X01
Pharming Technologies B.V.
primary immunodeficiency
1 trial -
LE 8201
Pharming Technologies B.V.
Common variable immunodeficiency
1 trial -
LE 1102
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
LE 5101
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
LE 6101
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial
Frequently asked questions
How many clinical projects does Pharming Technologies have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.